You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Homologous recombination (HR)

Showing 1 - 25 of 1,809
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

Not yet recruiting
  • Melanoma
  • Fluzoparib Camrelizumab Temozolomide
  • (no location specified)
Aug 9, 2023

Metastatic Melanoma Trial in San Francisco (Niraparib)

Recruiting
  • Metastatic Melanoma
  • San Francisco, California
    California Pacific Medical Center Research Institute
Oct 15, 2021

Triple Negative Breast Cancer Trial in Dallas (Drug 1: LY3023414; Drug 2: Prexasertib)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Drug 1: LY3023414; Drug 2: Prexasertib
  • Dallas, Texas
    Baylor University Medical Center
Jul 18, 2022

HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Completed
  • Epithelial Ovarian Cancer
  • +6 more
  • Evaluation of homologous recombination deficiency score
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Esophageal Cancer, Gastric Cancer, Adenocarcinoma Trial in United States (Niraparib)

Recruiting
  • Esophageal Cancer
  • +2 more
  • Tampa, Florida
  • +3 more
Jan 18, 2023

Metastatic Melanoma Trial in San Francisco (Olaparib, Pembrolizumab)

Recruiting
  • Metastatic Melanoma
  • San Francisco, California
    California Pacific Medical Center Research Institute
Apr 30, 2021

Breast Cancer Trial in Dallas (Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis)

Recruiting
  • Breast Cancer
  • Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
  • Dallas, Texas
    Baylor University Medical Center, Baylor Charles A Sammons Cance
Oct 7, 2021

Ovarian Cancer Trial in Pittsburgh (Olaparib tablet)

Not yet recruiting
  • Ovarian Cancer
  • Olaparib tablet
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Nov 1, 2023

Pancreatic Adenocarcinoma, Homologous Recombination Deficiency Trial (Cisplatin)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • Homologous Recombination Deficiency
  • (no location specified)
Oct 18, 2023

Breast Cancer, Breast Cancer Metastatic Trial in Spain (Niraparib 100 MG, Aromatase Inhibitors)

Terminated
  • Breast Cancer
  • Breast Cancer Metastatic
  • Niraparib 100 MG
  • Aromatase Inhibitors
  • A Coruña, Spain
  • +9 more
Jan 17, 2023

Testing Circulating Tumour DNA for Homologous Recombination Gene

Recruiting
  • Circulating Tumor DNA
  • Metastatic Prostate Cancer
  • Blood sample
  • Urine sample
  • Tours, France
    University hospital
Sep 6, 2022

Homologous Recombination Repair Pathway Gene Mutation Spectrum

Not yet recruiting
  • Breast Cancer
    • (no location specified)
    Jun 4, 2023

    HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

    Recruiting
    • HRD Cancer
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 20, 2023

    Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer Trial in Shanghai (Fluzoparib, Irinotecan)

    Not yet recruiting
    • Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
    • Shanghai, Shanghai, China
      Department of Colorectal Surgery Fudan University Shanghai Caner
    Feb 22, 2023

    Homologous Recombination Inquiry Through Ovarian Malignancy

    Completed
    • Ovarian Cancer
    • +2 more
      • Niigata city, Niigata Prefecture, Japan
        Niigata University Graduate School of Medical and Dental Science
      Jan 19, 2023

      HRD and Resistance to PAPPi in EOC Patients

      Recruiting
      • Epithelial Ovarian Cancer
      • +6 more
      • Testing of homologous recombination deficiency
      • Beijing, Beijing, China
        Lei Li
      Mar 26, 2022

      Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

      Active, not recruiting
      • Advanced Breast Cancer
      • +2 more
      • Talazoparib Tosylate
      • Stanford, California
        Stanford University Hospitals and Clinics
      Nov 16, 2022

      Solid Tumor, Adult Trial in Miami (Pembrolizumab 200 mg Q3W)

      Active, not recruiting
      • Solid Tumor, Adult
      • Pembrolizumab 200 mg Q3W
      • Miami, Florida
        Miami Cancer Institute at Baptist Health, Inc.
      Nov 18, 2022

      Homologous Recombination Deficiency, Triple Negative Breast Cancer Trial (Niraparib)

      Not yet recruiting
      • Homologous Recombination Deficiency
      • Triple Negative Breast Cancer
      • (no location specified)
      Jul 15, 2022

      High-Grade Ovarian Cancer Terms of Homologous Recombination

      Not yet recruiting
      • Ovarian Cancer
      • +2 more
      • Standard of care
      • (no location specified)
      Oct 7, 2022

      Breast Cancer Trial in Amsterdam (carboplatin, thiotepa, and cyclophosphamide, chemo (docetaxel, doxorubicin, cyclofosfamide,

      Recruiting
      • Breast Cancer
      • carboplatin, thiotepa, and cyclophosphamide
      • chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
      • Amsterdam, Netherlands
        NKI-AVL
      Mar 21, 2022

      Homologous Recombination-related Genesmutationsand HRD in Breast

      Not yet recruiting
      • Breast Cancer
      • HER2-low Breast Cancer
      • Standard Management
      • Guangzhou, Guangdong, China
        Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
      Jul 18, 2022

      Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

      Recruiting
      • Lung Cancer
        • Shanghai, China
          Shanghai Chest Hospital
        Jul 20, 2023

        Solid Tumor, Adult, Homologous Recombination Deficiency Trial in Washington, Hackensack, Charlotte (Niraparib, Carboplatin)

        Recruiting
        • Solid Tumor, Adult
        • Homologous Recombination Deficiency
        • Washington, District of Columbia
        • +2 more
        Aug 31, 2021

        Advanced Cancers Trial in Boston (LY2606368)

        Active, not recruiting
        Has Results
        • Advanced Cancers
        • Boston, Massachusetts
          Dana Farber Cancer Institute
        Jan 18, 2022